By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nimbus Discovery today announced an extension of its seed round of funding, which will be used to advance drug programs based on its in silco discovery platform.

The funding comes from Bill Gates and Richard Freisner, co-founder of chemical simulation software firm Schrödinger and a professor of chemistry at Columbia University. Atlas Venture, the founding investor in Nimbus, also was a participant.

Nimbus did not disclose the amount of the investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.